PureTech Health plc

Business Wire

Thu, Aug 28, 2025, 2:00 AM 55 min read

Achieved meaningful progress toward key value inflection points across our diversified portfolio, with multiple programs advancing into or toward late-stage development

Launch of Celea Therapeutics continues our proven, capital-efficient model

Maintained a strong financial position with $319.6M PureTech level cash, cash equivalents and short-term investments and $319.9M Consolidated cash, cash equivalents and short-term investments as of June 30, 2025; operational runway into 2028 enables flexibility to drive early-stage innovation while evaluating opportunities for capital returns

Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST

BOSTON, August 28, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announces its half-yearly results for the six months ended June 30, 2025. The following information will be filed on Form 6-K with the United States Securities and Exchange Commission (the "SEC") and is also available at https://investors.puretechhealth.com/financials-filings/reports.

Commenting on PureTech's half-yearly results, Robert Lyne, Interim Chief Executive Officer of PureTech, said:

"We entered 2025 with significant momentum, and our progress in the first half of the year further underscores the strength and breadth of our portfolio and model.

We are refining our strategy in a way that builds on what PureTech does best: identifying and clinically de-risking high-potential programs internally and then advancing and scaling them through our Founded Entities supported by external capital. This hub-and-spoke model enables us to operate with discipline and flexibility, addressing urgent patient needs while also maintaining meaningful upside and long-term value creation for PureTech shareholders.

Looking ahead, our approach to capital allocation will be guided by an efficient use of cash and prioritizing spend that is truly value accretive to shareholders. Practically, this means optimizing spend on current and any new programs to reach key inflection points, after which programs can be advanced through Founded Entities or other structures with dedicated operational capacity and external financing. In many ways, this represents a return to the core strengths that have always defined PureTech – a capital-efficient engine for high-impact innovation – as demonstrated by the $1 billion in proceeds generated from Karuna and the recent launch of Celea Therapeutics to advance deupirfenidone which has delivered compelling Phase 2b data.